Roquefort Therapeutics today announces its annual results ended 31 December 2022. Operating loss was £1.6m and net cash was £2.3m as of 31 December 2022. Roquefort remains on track to achieve clinical readiness in 2H23 for one of its four highly synergistic programs: Midkine antibodies, Midkine RNA, MK Cell Therapies and STAT-6, siRNA. The siRNA, MK cell therapy and Midkine RNA oligonucleotide programs are expected to complete pre-clinical development milestones in 2Q23. The completion of pre-c ....